3rd Circ. Revives Lipitor, Effexor Antitrust Claims

By Brian Amaral (August 21, 2017, 4:51 PM EDT) -- The Third Circuit on Monday handed a sweeping victory to buyers of cholesterol drug Lipitor and antidepressant drug Effexor XR, reviving their antitrust claims for alleged patent fraud and anti-competitive reverse payment schemes.

The decision entirely reinstates the suit against Pfizer and generic-drug maker Ranbaxy over Lipitor, which had been dismissed entirely, and gives new life to claims against Pfizer unit Wyeth and Teva Pharmaceuticals for Effexor, which had been dismissed in part. (AP) The suits, the appellate panel found in the multidistrict litigation, plausibly alleged various ploys to artificially inflate the costs of the two drugs to make it past the dismissal...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!